(Q57601995)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15772741%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

title

Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15772741%20AND%20SRC:MED&resulttype=core&format=json

relapsing-remitting multiple sclerosis

9 January 2020

main subject

multiple sclerosis

0 references

0 references

author

Jordi Rio

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15772741%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Mar Tintoré

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15772741%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Ingrid Galán

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15772741%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Xavier Montalban

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15772741%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

Carlos Nos

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15772741%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Nieves Téllez

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15772741%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

publication date

18 March 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15772741%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15772741%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

252

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15772741%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15772741%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

795-800

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15772741%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00415-005-0748-5

9 January 2020

exact match

0 references

cites work

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0748-5

The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0748-5

Randomized controlled trials to assess therapies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0748-5

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0748-5

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0748-5

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Randomized trials or observational tribulations?

1 reference

12 December 2020

Randomized, controlled trials, observational studies, and the hierarchy of research designs

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

1 reference

12 December 2020

Interferons in relapsing remitting multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

A comparison of observational studies and randomized, controlled trials

1 reference

12 December 2020

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

12 December 2020

Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy

1 reference

12 December 2020

Clinical characteristics of responders to interferon therapy for relapsing MS.

1 reference

12 December 2020

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

12 December 2020

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

12 December 2020

The natural history of multiple sclerosis

1 reference

12 December 2020

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

1 reference

12 December 2020

Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre

1 reference

12 December 2020

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

10.1007/S00415-005-0748-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15772741%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference